DR
Dermata Therapeutics, Inc.
DRMAW · NASDAQ
$0.00 -97.38% (-$0.02)
1M -50.00%
Market Cap $408.0
P/E Ratio -
Div. Yield -
ROE 166.67%
Bulios Fair Price
$0
100.0% downside
Current Price
$0.0006
Undervalued Fair Value Overvalued
According to Bulios Fair Price, DRMAW is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
0/9Valuation
100 /100
Cheap P/B 0.00x
EV/EBITDA N/A
P/S N/A
Growth
31 /100
Declining Book val. growth 1.10%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 166.67%
ROA 157.28%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 2.81x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
37 /100
Moderate EPS volatility 157.17%
Profitable years 0
Beta 0.66x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about DRMAW
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Gerald T. Proehl
Employees
9
Headquarters
San Diego
Upcoming events
18 NOV
Earnings
Upcoming earnings report